Pathogen inactivation: Making decisions about new technologies - Report of a consensus conference

Transfusion

Volumn 47, Issue 12, 2007, Pages 2338-2347

  Klein, Harvey G ^a   Anderson, David ^b   Bernardi, Marie Josée ^b   Cable, Ritchard ^b   Carey, William ^b   Hoch, Jeffrey S ^b   Robitaille, Nancy ^b   Sivilotti, Marco L A ^b   Smaill, Fiona ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FRESH FROZEN PLASMA;

BABESIOSIS; BACTERIAL TRANSMISSION; BACTERIUM CONTAMINATION; BLOOD COMPONENT; BLOOD TRANSFUSION; CHAGAS DISEASE; CONFERENCE PAPER; COST BENEFIT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; DONOR SELECTION; ERYTHROCYTE; HEALTH CARE DELIVERY; HEALTH CARE POLICY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALARIA; MEDICAL DECISION MAKING; MEDICAL TECHNOLOGY; PATHOGENICITY; PATIENT IDENTIFICATION; POPULATION RESEARCH; POSTMARKETING SURVEILLANCE; RISK ASSESSMENT; SEPSIS; THROMBOCYTE; TOXICOLOGY; VIRUS INFECTION; WEST NILE FLAVIVIRUS;

BIOMEDICAL TECHNOLOGY; BLOOD TRANSFUSION; DECISION MAKING; HUMANS;

EID: 36348962917     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2007.01512.x     Document Type: Conference Paper

References (80)

1. Burnouf T, Radosevich M. Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev 2000 14 : 94 110.
2. Solheim BG. Universal pathogen-reduced plasma in elective open-heart surgery and liver resection. Clin Med Res 2006 4 : 209 17.
3. Politis C, Kavallierou L, Hantziara S, Katsea P, Triantaphylou V, Richardson C, Tsoutsos D, Anagnostopoulos N, Gorgolidis G, Ziroyannis P. Quality and safety of fresh-frozen plasma inactivated and leucoreduced with the Theraflex methylene blue system including the Blueflex filter: 5 years' experience. Vox Sang 2007 92 : 319 26.
4. Janetzko K, Cazenave JP, Kluter H, Kientz D, Michel M, Beris P, Lioure B, Hastka J, Marblie S, Mayaudon V, Lin L, Lin JS, Conlan MG, Flament J. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005 45 : 1443 52.
5. Bryant BJ, Klein HG. Pathogen inactivation: the definitive safeguard for the blood supply. Arch Pathol Lab Med 2007 131 : 719 33.
6. Ferguson JH the NIH Consensus Development Program. The evolution of guidelines. Int J Technol Assess Health Care 1996 12 : 460 74.
7. Wortman PM, Vinokur A, Sechrest L. Do consensus conferences work? A process evaluation of the NIH Consensus Development Program. J Health Polit Policy Law 1988 13 : 469 98.
8. Klein HG, Anderson D, Bernardi MJ, Cable R, Carey W, Hoch JS, Robitaille N, Sivilotti ML, Smaill F. Pathogen inactivation: making decisions about new technologies - preliminary report of a consensus conference. Vox Sang 2007 93 : 179 82.
9. Allain JP, Bianco C, Blajchman MA, Brecher ME, Busch M, Leiby D, Lin L, Stramer S. Protecting the blood supply from emerging pathogens: the role of pathogen inactivation. Transfus Med Rev 2005 19 : 110 26.
10. Williamson LM, Cardigan R, Prowse CV. Methylene blue-treated fresh-frozen plasma: what is its contribution to blood safety? Transfusion 2003 43 : 1322 9.
11. Pelletier JP, Transue S, Snyder EL. Pathogen inactivation techniques. Best Pract Res Clin Haematol 2006 19 : 205 42.
12. O'Brien SF, Yi QL, Fan W, Scalia V, Kleinman SH, Vamvakas EC. Current incidence and estimated residual risk of transfusion-transmitted infections in donations made to Canadian Blood Services. Transfusion 2007 47 : 316 25.
13. Dodd RY, Notari EP, Stramer SL. Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 2002 42 : 975 9.
14. Soldan K, Barbara JA, Ramsay ME, Hall AJ. Estimation of the risk of hepatitis B virus, hepatitis C virus and human immunodeficiency virus infectious donations entering the blood supply in England, 1993-2001. Vox Sang 2003 84 : 274 86.
15. Pillonel J, Laperche S. Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill 2005 10 : 5 8.
16. Velati C, Fomiatti L, Baruffi L, Romano L, Zanetti A. Impact of nucleic acid amplification technology (NAT) in Italy in the three years following implementation (2001-2003). Euro Surveill 2005 10 : 12 4.
17. Niederhauser C, Schneider P, Fopp M, Ruefer A, Levy G. Incidence of viral markers and evaluation of the estimated risk in the Swiss blood donor population from 1996 to 2003. Euro Surveill 2005 10 : 14 6.
18. Alvarez do Barrio M, Gonzalez Diez R, Hernandez Sanchez JM, Oyonarte Gomez S. Residual risk of transfusion-transmitted viral infections in Spain, 1997-2002, and impact of nucleic acid testing. Euro Surveill 2005 10 : 20 2.
19. Offergeld R, Faensen D, Ritter S, Hamouda O. Human immunodeficiency virus, hepatitis C and hepatitis B infections among blood donors in Germany 2000-2002: risk of virus transmission and the impact of nucleic acid amplification testing. Euro Surveill 2005 10 : 8 11.
20. Coste J, Reesink HW, Engelfriet CP, Laperche S, Brown S, Busch MP, Cuijpers HT, Elgin R, Ekermo B, Epstein JS, Flesland O, Heier HE, Henn G, Hernandez JM, Hewlett IK, Hyland C, Keller AJ, Krusius T, Levicnik-Stezina S, Levy G, Lin CK, Margaritis AR, Muylle I, Neiderhauser C, Pastila S, Pillonel J, Pineau J, van der Poel CI, Politis C, Roth WK, Sauleda S, Seed CR, Sondag-Thull D, Stramer SI, Strong M, Vamvakas EC, Velati C, Vesga MA, Zanetti A. Implementation of donor screening for infectious agents transmitted by blood by nucleic acid technology: update to 2003. Vox Sang 2005 88 : 289 303.
21. Bihl F, Castelli D, Marincola F, Dodd RY, Brander C. Transfusion- transmitted infections. J Transl Med 2007 5 : 25.
22. Pittman M. A study of bacteria implicated in transfusion reactions and of bacteria isolated from blood products. J Lab Clin Med 1953 42 : 273 88.
23. Yomtovian RA, Palavecino EL, Dysktra AH, Downes KA, Morrissey AM, Bajaksouzian S, Pokorny MA, Lazarus HM, Jacobs MR. Evolution of surveillance methods for detection of bacterial contamination of platelets in a university hospital, 1991 through 2004. Transfusion 2006 46 : 719 30.
24. Ramirez-Arcos S, Jenkins C, Dion J, Bernier F, Delage G, Goldman M. Canadian experience with detection of bacterial contamination in apheresis platelets. Transfusion 2007 47 : 421 9.
25. Fang CT, Chambers LA, Kennedy J, Strupp A, Fucci MC, Janas JA, Tang Y, Hapip CA, Lawrence TB, Dodd RY. Detection of bacterial contamination in apheresis platelet products: American Red Cross experience, 2004. Transfusion 2005 45 : 1845 52.
26. Ness P, Braine H, King K, Barrasso C, Kickler T, Fuller A, Blades N. Single-donor platelets reduce the risk of septic platelet transfusion reactions. Transfusion 2001 41 : 857 61.
27. Eder AF, Kennedy JM, Dy BA, Notari EP, Weiss JW, Fang CT, Wagner S, Dodd RY, Benjamin RJ. Bacterial screening of apheresis platelets and the residual risk of septic transfusion reactions: the American Red Cross experience (2004-2006). Transfusion 2007 47 : 1134 42.
28. Stramer SL. Current risks of transfusion-transmitted agents: a review. Arch Pathol Lab Med 2007 131 : 702 7.
29. Cable RG, Leiby DA. Risk and prevention of transfusion-transmitted babesiosis and other tick-borne diseases. Curr Opin Hematol 2003 10 : 405 11.
30. Leiby DA. Threats to blood safety posed by emerging protozoan pathogens. Vox Sang 2004 87 Suppl 2 : 120 2.
31. Vamvakas EC, Kleinman S, Hume H, Sher GD. The development of West Nile virus safety policies by Canadian blood services: guiding principles and a comparison between Canada and the United States. Transfus Med Rev 2006 20 : 97 109.
32. Stainsby D, Jones H, Asher D, Atterbury C, Boncinelli A, Brant L, Chapman CE, Davison K, Gerrard R, Gray A, Knowles S, Love EM, Milkins C, McClelland DBL, Norfolk DR, Soldan K, Taylor C, John Revill J, Williamson LM, Cohen H SHOT Steering Group. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006 20 : 273 82.
33. Toy P, Popovsky MA, Abraham E, Ambruso DR, Holness LG, Kopko PM, Mcfarland JG, Nathens AB, Silliman CC, Stroncek D. Transfusion-related acute lung injury: definition and review. Crit Care Med 2005 33 : 721 6.
34. Eder AF, Herron R, Strupp A, Dy B, Notari EP, Chambers LA, Dodd RY, Benjamin RJ. Transfusion-related acute lung injury surveillance (2003-2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 2007 47 : 599 607.
35. Linden JV, Wagner K, Voytovich AE, Sheehan J. Transfusion errors in New York State: an analysis of 10 years' experience. Transfusion 2000 40 : 1207 13.
36. Alter HJ, Stramer SL, Dodd RY. Emerging infectious diseases that threaten the blood supply. Semin Hematol 2007 44 : 32 41.
37. Kroner BL, Rosenberg PS, Aledort LM, Alvord WG, Goedert JJ. HIV-1 infection incidence among persons with hemophilia in the United States and western Europe, 1978-1990. Multicenter Hemophilia Cohort Study. J Acquir Immune Defic Syndr 1994 7 : 279 86.
38. A Canadian perspective on the precautionary approach/principle [monograph on the Internet]. Environment Canada 2001 cited 2007 Oct 30]. Available from: http://www.ec.gc.ca/econom/pamplet_e.htm
39. Stoto MA. The precautionary principle and emerging biologic risks: lessons from human immunodeficiency virus in blood products. Semin Hematol 2006 43 (2 Suppl 3 S10 S12.
40. Davies A, Staves J, Kay J, Casbard A, Murphy MF. End-to-end electronic control of the hospital transfusion process to increase the safety of blood transfusion: strengths and weaknesses. Transfusion 2006 46 : 352 64.
41. Dzik WH. New technology for transfusion safety. Br J Haematol 2007 136 : 181 90.
42. Chang MH. Hepatitis B virus infection. Semin Fetal Neonatal Med 2007 12 : 160 7.
43. Galea G, Urbaniak SJ. The incidence and consequences of cytomegalovirus transmission via blood transfusion to low birth weight, premature infants in north east Scotland. Vox Sang 1992 62 : 200 7.
44. Aach RD, Yomtovian RA, Hack M. Neonatal and pediatric posttransfusion hepatitis C: a look back and a look forward. Pediatrics 2000 105 (4 Pt 1 836 42.
45. Casiraghi MA, Romano L, Biffi R, Assi A, Binelli G, Zanetti AR. Long-term outcome (35 years) of hepatitis C after acquisition of infection through mini transfusions of blood given at birth. Hepatology 2004 39 : 90 6.
46. Pharmacology/Toxicology guidance documents [monograph on the Internet]. US Food and Drug Administration 2006 cited 2007 Oct 30]. Available from: http://www.fda.gov/cder/guidance/index.htm#Pharmacology/Toxicology
47. International Conference on Harmonization (ICH) safety guidelines [monograph on the Internet]. Health Canada 2007 cited 2007 Oct 30]. Available from: http://www.hc-sc.gc.ca/dhp-mps/prodpharma/applic-demande/guide-ld/ich/ securit/index_e.html
48. Chapman JR, Moore K, Butterworth BE. Pathogen inactivation of RBCs: PEN110 reproductive toxicology studies. Transfusion 2003 43 : 1386 93.
49. Ciaravi V, Mccullough T, Dayan AD. Pharmacokinetic and toxicology assessment of INTERCEPT (S-59 and UVA treated) platelets. Hum Exp Toxicol 2001 20 : 533 50.
50. Goodrich RP. The use of riboflavin for the inactivation of pathogens in blood products. Vox Sang 2000 78 Suppl 2 : 211 5.
51. Orzack LH, Kaitin KI, Lasagna L. Pharmaceutical regulation in the European Community: barriers to single market integration. J Health Polit Policy Law 1992 17 : 847 68.
52. Breckenridge A, Woods K. Medicines regulation and the pharmaceutical industry. BMJ 2005 331 : 834 6.
53. Kesselheim AS, Mello MM. Confidentiality laws and secrecy in medical research: improving public access to data on drug safety. Health Aff (Millwood) 2007 26 : 483 91.
54. Farrugia A. The regulatory pendulum in transfusion medicine. Transfus Med Rev 2002 16 : 273 82.
55. Ravaud P, Tubach F. Methodology of therapeutic trials: lessons from the late evidence of the cardiovascular toxicity of some coxibs. Joint Bone Spine 2005 72 : 451 5.
56. Psaty BM, Burke SP. Protecting the health of the public - Institute of Medicine recommendations on drug safety. N Engl J Med 2006 355 : 1753 5.
57. McClellan M. Drug safety reform at the FDA - pendulum swing or systematic improvement? N Engl J Med 2007 356 : 1700 2.
58. Kelly L, Lazzaro M, Petersen C. Canadian drug regulatory framework. Can J Neurol Sci 2007 34 Suppl 1 : S3 10.
59. O'Brien SF, Ram SS, Vamvakas EC, Goldman M. The Canadian blood donor health assessment questionnaire: lessons from history, application of cognitive science principles, and recommendations for change. Transfus Med Rev 2007 21 : 205 22.
60. Orton SL, Stramer SL, Dodd RY. Self-reported symptoms associated with West Nile virus infection in RNA-positive blood donors. Transfusion 2006 46 : 272 7.
61. Grass JA, Wafa T, Reames A, Wages D, Corash L, Ferrara JL, Lin L. Prevention of transfusion-associated graft-versus-host disease by photochemical treatment. Blood 1999 93 : 3140 7.
62. Roback JD, Hossain MS, Lezhava L, Gorechlad JW, Alexander SA, Jaye DL, Mittelstaedt S, Talib S, Hearst JE, Hillyer CD, Waller EK. Allogeneic T cells treated with amotosalen prevent lethal cytomegalovirus disease without producing graft-versus-host disease following bone marrow transplantation. J Immunol 2003 171 : 6023 31.
63. Fast LD, Dileone G, Cardarelli G, Li J, Goodrich R. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2-/-gamma c-/- double knockout mice. Transfusion 2006 46 : 1553 60.
64. Epstein JS, Vostal JG. FDA approach to evaluation of pathogen reduction technology. Transfusion 2003 43 : 1347 50.
65. Sunstein CR. Laws of fear: beyond the precautionary principle. Cambridge (UK) : Cambridge University Press 2005.
66. Jackson BR, Aubuchon JP, Birkmeyer JD. Update of cost-effectiveness analysis for solvent-detergent-treated plasma. JAMA 1999 282 : 329.
67. Pereira A. Cost-effectiveness of transfusing virus-inactivated plasma instead of standard plasma. Transfusion 1999 39 : 479 87.
68. Riedler GF, Haycox AR, Duggan AK, Dakin HA. Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 2003 85 : 88 95.
69. Bell CE, Botteman MF, Gao X, Weissfeld JL, Postma MJ, Pashos CL, Triulzi D, Staginnus U. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. Clin Ther 2003 25 : 2464 86.
70. Staginnus U, Corash L. Economics of pathogen inactivation technology for platelet concentrates in Japan. Int J Hematol 2004 80 : 317 24.
71. Postma MJ, van Hulst M, de Wolf JT, Botteman M, Staginnus U. Cost-effectiveness of pathogen inactivation for platelet transfusions in the Netherlands. Transfus Med 2005 15 : 379 87.
72. Moeremans K, Warie H, Annemans L. Assessment of the economic value of the INTERCEPT blood system in Belgium. Transfus Med 2006 16 : 17 30.
73. Custer B. Economic analyses of blood safety and transfusion medicine interventions: a systematic review. Transfus Med Rev 2004 18 : 127 43.
74. van Hulst M, de Wolf JT, Staginnus U, Ruitenberg EJ, Postma MJ. Pharmaco-economics of blood transfusion safety: review of the available evidence. Vox Sang 2002 83 : 146 55.
75. Detsky AS, Laupacis A. Relevance of cost-effectiveness analysis to clinicians and policy makers. JAMA 2007 298 : 221 4.
76. Gold M, Siegel J, Russell L, Weinstein M. Cost-effectiveness in health and medicine. New York : Oxford University Press 1996.
77. Mauskopf JA, Paul JE, Grant DM, Stergachis A. The role of cost-consequence analysis in healthcare decision-making. Pharmacoeconomics 1998 13 : 277 88.
78. Barbara JA. The rationale for pathogen-inactivation treatment of blood components. Int J Hematol 2004 80 : 311 6.
79. Turner ML. Prion reduction filters. Lancet 2006 368 : 2190 1.
80. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? Interpreting zero numerators. JAMA 1983 249 : 1743 5.